AstraZeneca and Merck & Co announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib). The approval is as follows: New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primarAlready a subscriber Login You have read all your free articles,…